Febbo Phillip G. 4

What Happened

• Phillip G. Febbo, Veracyte's Chief Scientific & Medical Officer, was reported as receiving an award of 71,806 performance-based restricted stock units (PSUs) on Feb 26, 2026. The filing shows the award at $0.00 per share (standard for RSU/PSU grants).
• Of the PSUs, 47,863 vested on Feb 26, 2026 upon board certification of the performance goals; 23,943 remain subject to vesting on Dec 2, 2026, contingent on continued service.
• To satisfy tax withholding related to the vesting, 24,486 shares were withheld at $38.75 per share (value ~ $948,833). The withheld shares were not sold on the open market.

Key Details

• Transaction date: February 26, 2026; Form 4 filed March 2, 2026.
• Reported transactions: A (award/acquisition) — 71,806 PSUs @ $0.00; F (tax withholding) — 24,486 shares withheld @ $38.75, total withheld value ≈ $948,833.
• Vesting breakdown: 47,863 PSUs vested on Feb 26, 2026; 23,943 PSUs scheduled to vest on Dec 2, 2026 (subject to continued service).
• Withheld shares do not represent a sale by the insider — they were used to satisfy tax obligations.
• Shares owned after the transaction: not specified in the filing.
• Filing timeliness: filing date is March 2, 2026 (report covers Feb 26 transactions); the Form 4 shows the transactions and withholding as described.

Context

• These were performance-based RSUs (PSUs); vesting occurred only after the Board certified achievement of performance goals. The withholding of shares to cover taxes is a routine administrative step and does not indicate an open-market sale.
• For retail investors, awards and vesting primarily reflect compensation realization rather than directional trades; purchases are generally more indicative of bullish insider sentiment than routine vesting events.